- Home
- AIO vs RIGL Comparison
AIO vs RIGL Comparison
Compare AIO & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AIO | RIGL |
|---|---|---|
| Founded | 2019 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 777.8M | 628.4M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | AIO | RIGL |
|---|---|---|
| Price | N/A | $27.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | | 3 |
| Target Price | N/A | $45.67 |
| AVG Volume (30 Days) | N/A | 287.1K |
| Earning Date | 04-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | 1867.68 |
| EPS | N/A | 19.48 |
| Revenue | N/A | $294,282,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.75 |
| P/E Ratio | N/A | $1.41 |
| Revenue Growth | N/A | 64.15 |
| 52 Week Low | N/A | $15.50 |
| 52 Week High | N/A | $52.24 |
Technical Indicators
Market Signals| Indicator | AIO | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 48.23 | 43.51 |
| Support Level | $21.66 | $26.38 |
| Resistance Level | $23.48 | $30.59 |
| Average True Range (ATR) | 0.49 | 0.93 |
| MACD | 0.04 | 0.48 |
| Stochastic Oscillator | 66.92 | 79.35 |
Price Performance
Historical ComparisonAbout AIO Virtus Artificial Intelligence & Technology Opportunities Fund of Beneficial Interest
Virtus Artificial Intelligence & Technology Opportunities Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.